Stage-dependent doxorubicin toxicity impairs C2C12 myogenesis via AMPK/AKT-FOXO signaling and is attenuated by metformin
Environmental Toxicology and Pharmacology · 2026
DOI: 10.1016/j.etap.2026.105147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology and Pharmacology, 2026. Verfasst von Sou Hyun Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea. Hauptthemen laut MEDLINE: Doxorubicin, Metformin, Muscle Development, Antibiotics, Antineoplastic. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Korea Ministry of Science and ICT.
Abstract (Originalsprache)
Doxorubicin (DOX) can compromise skeletal muscle, but whether toxicity depends on myogenic stage is unclear. C2C12 myoblasts were exposed to non‑cytotoxic DOX (0.025-0.1 μg/mL) before differentiation (24 h) or after 3 days of differentiation (48 h), with or without metformin (Met; 0.1-2 mM). Pre‑differentiation DOX markedly impaired later myotube formation, whereas post‑differentiation DOX disrupted myotube maturation. Both regimens reduced myogenin and myosin heavy chain expression and suppressed AMP‑activated protein kinase (AMPK) and AKT phosphorylation. DOX activated a FOXO transcription factor-dependent catabolic program, decreasing inhibitory phosphorylation of FOXO3a (and FOXO1 post‑differentiation) and increasing MAFbx and MuRF1. Met co‑treatment partially preserved myotube integrity and myogenic markers, reactivated AMPK, partially recovered AKT signaling, and attenuated FOXO-MAFbx/MuRF1 induction. These findings define stage-dependent DOX myotoxicity and suggest that Met-associated AMPK reactivation may partially mitigate DOX-induced myogenic dysfunction under defined in vitro conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea.
- Advanced Biotechnology Cluster, KIST Europe Forschungsgesellschaft mbH, Saarbrücken, 66123, Germany.
- College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea. Electronic address: sangkim@cnu.ac.kr.
- Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea. Electronic address: youngjung@pusan.ac.kr.
Förderung
- National Research Foundation of Korea
- Korea Ministry of Science and ICT
Zitieren
APA
Kim, S. H., Ryu, C. S., Yun, C., Woo, R., Kim, S. K., & Jung, Y. S. (2026). Stage-dependent doxorubicin toxicity impairs C2C12 myogenesis via AMPK/AKT-FOXO signaling and is attenuated by metformin. Environmental Toxicology and Pharmacology. https://doi.org/10.1016/j.etap.2026.105147
Vancouver
Kim SH, Ryu CS, Yun C, Woo R, Kim SK, Jung YS. Stage-dependent doxorubicin toxicity impairs C2C12 myogenesis via AMPK/AKT-FOXO signaling and is attenuated by metformin. Environmental Toxicology and Pharmacology. 2026. doi:10.1016/j.etap.2026.105147
BibTeX
@article{Kim2026,
author = {Kim, Sou Hyun and Ryu, Chang Seon and Yun, Chawon and Woo, RanJu and Kim, Sang Kyum and Jung, Young-Suk},
title = {Stage-dependent doxorubicin toxicity impairs C2C12 myogenesis via AMPK/AKT-FOXO signaling and is attenuated by metformin},
journal = {Environmental Toxicology and Pharmacology},
year = {2026},
doi = {10.1016/j.etap.2026.105147}
}
EUVIMED